Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 3,155 matching trials from the live ClinicalTrials.gov search.

Filters: San Antonio, Texas Clear all

Conditions: Leukemia
Interventions: asparaginase, cytarabine, daunorubicin hydrochloride, etoposide, gemtuzumab ozogamicin, mitoxantrone hydrochloride; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 29 Years
Enrollment: 1,070 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2020
U.S. locations: 178
States / cities: Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 141 more

Conditions: Psoriasis Vulgaris
Interventions: Calcipotriol plus betamethasone, Betamethasone-17,21-dipropionate, Calcipotriene, Topical suspension vehicle; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 1,152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 59
States / cities: Mobile, Alabama • Hot Springs, Arkansas • Anaheim, California + 50 more

Conditions: Lung Transplantation
Interventions: Not listed
Lead sponsor: University of Alberta; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Timeline: 2023 – 2028
U.S. locations: 12
States / cities: Phoenix, Arizona • Gainesville, Florida • Jacksonville, Florida + 8 more

Conditions: Urinary Incontinence, Stress
Interventions: Active treatment, Sham; Device
Lead sponsor: Viveve Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 29
States / cities: Mobile, Alabama • Tucson, Arizona • Long Beach, California + 25 more

Conditions: Post Traumatic Stress Disorder
Interventions: Soterix 1x1 tDCS mini CT, Sham Soterix 1x1 tDCS Mini CT, Written Exposure Therapy (WET); Device · Other · Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pneumococcal Infection
Interventions: V116, PCV20; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 2,663 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 60
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 52 more

Conditions: Type2 Diabetes Mellitus, Cardiovascular Diseases
Interventions: Canagliflozin 300mg, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Foot Ulcer, Diabetes
Interventions: KC-002, Conventional Wound Therapy; Device · Other
Lead sponsor: KeraCure; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 21
States / cities: Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 18 more

Conditions: Ulcerative Colitis
Interventions: SPD476, Asacol; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 829 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 15
States / cities: Birmingham, Alabama • Bristol, Connecticut • Washington D.C., District of Columbia + 12 more

Conditions: Tooth Extraction
Interventions: Combination 70% FDBA and 30% DFDBA, OsteoGen Plug; Device
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 89 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Lung Cancer
Interventions: carboplatin, paclitaxel, tirapazamine; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2006
U.S. locations: 93
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more

Conditions: Breast Cancer
Interventions: FFDM Mammography, DBT Mammography; Device
Lead sponsor: Fujifilm Medical Systems USA, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 5
States / cities: Scottsdale, Arizona • Iowa City, Iowa • Rochester, New York + 2 more

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Alemtuzumab, Interferon beta-1a; Biological
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 581 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 36
States / cities: Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 31 more

Conditions: Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
Interventions: KRT-232, Best Available Therapy (BAT); Drug
Lead sponsor: Kartos Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Stanford, California + 14 more

Conditions: Acute Lymphoblastic Leukemia
Interventions: Discussion, Medical Chart Review, Questionnaire Administration; Behavioral · Other
Lead sponsor: Children's Oncology Group; Network
Eligibility: 15 Years to 39 Years
Enrollment: 301 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2024
U.S. locations: 480
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Fort Smith, Arkansas + 302 more

Conditions: Atherosclerosis
Interventions: Selnoflast, Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 24
States / cities: Beverly Hills, California • Irvine, California • Los Angeles, California + 19 more

Conditions: Kidney Cancer
Interventions: alvocidib; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 101
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more

Conditions: Kidney Cancer
Interventions: OSI-774; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Pembrolizumab, Photon Beam Radiation Therapy, Positron Emission Tomography, Questionnaire Administration, Transurethral Resection of Bladder Tumor; Procedure · Biological · Radiation + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 182
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 146 more

Conditions: Overweight
Interventions: Weight Maintenance, Weight Maintenance + Intermittent Fasting; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 50 Years to 75 Years
Enrollment: 175 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Baltimore, Maryland • San Antonio, Texas

Conditions: Non-Small Cell Lung Cancer
Interventions: Livmoniplimab, Budigalimab, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 19
States / cities: La Jolla, California • Pembroke Pines, Florida • Winter Haven, Florida + 16 more

Conditions: Relapsed or Refractory Large B-cell Lymphoma
Interventions: Axicabtagene Ciloleucel, Cyclophosphamide, Fludarabine, Dexamethasone; Biological · Drug
Lead sponsor: Kite, A Gilead Company; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 16
States / cities: Duarte, California • Los Angeles, California • Denver, Colorado + 12 more

Conditions: Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Interventions: Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only), Lurbinectedin (regions/countries where approved and available); Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 695 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 20
States / cities: Anchorage, Alaska • Hot Springs, Arkansas • Anaheim, California + 16 more

Conditions: Invasive Mold Infections
Interventions: Fosmanogepix IV infusion, Standard of care antifungal therapy, Fosmanogepix oral tablet; Drug
Lead sponsor: Basilea Pharmaceutica; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 20
States / cities: Birmingham, Alabama • Duarte, California • Los Angeles, California + 15 more

Search by objective public record fields.

Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia

LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)

Trifecta-Lung cfDNA-MMDx Study

Prospective US Radiofrequency SUI Trial

Transcranial Direct Current Stimulation (tDCS) in Human Subjects With PTSD Receiving an Exposure-based, Behavioral Therapy

Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults (V116-003, STRIDE-3)

Effects of Canagliflozin on Intravascular Volume and Hemodynamics

Safety and Efficacy Study of an Interactive Wound Dressing (KC002) for the Treatment of Diabetic Foot Ulcers

Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis

Wound Healing Following Tooth Extraction and Ridge Preservation Using OsteoGen®

Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Acquisition of Breast Mammography Images

Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia

A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events

Flavopiridol in Treating Patients With Unresectable or Metastatic Kidney Cancer

Erlotinib in Treating Patients With Advanced Kidney Cancer

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Promotion of Weight Management

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.